Stereotactic and functional neurosurgery 2017
Impact of the Number of Metastatic Tumors Treated by Stereotactic Radiosurgery on the Dose to Normal Brain: Implications for Brain Protection.
Abstract
Purpose/objectives
The purpose of this study was to evaluate the effect of the number of brain lesions for which stereotactic radiosurgery (SRS) was performed on the dose volume relationships in normal brain.
Materials and methods
Brain tissue was segmented using the patient's pre-SRS MRI. For each plan, the following data points were recorded: total brain volume, number of lesions treated, volume of brain receiving 8 Gy (V8), V10, V12, and V15.
Results
A total of 225 Gamma Knife® treatments were included in this retrospective analysis. The number of lesions treated ranged from 1 to 29. The isodose for prescription ranged from 40 to 95% (mean 55%). The mean prescription dose to tumor edge was 18 Gy. The mean coverage, selectivity, conformity, and gradient index were 97.5%, 0.63, 0.56, and 3.5, respectively. The mean V12 was 9.5 cm3 (ranging from 0.5 to 59.29). There was no correlation between the number of lesions and brain V8, V12, V10, or V15. There was a direct and statistically significant relationship between the brain volume treated (V8, V10, V12, and V15) and total volume of tumors treated (p < 0.001). In our study, the integral dose to the brain exceeded 3 J when the total tumor volume exceeded 25 cm3.
Conclusions
The number of metastatic brain lesions treated bears no significant relationship to total brain tissue volume treated when using SRS. The fact that the integral dose to the brain exceeded 3 J when the total tumor volume exceeded 25 cm3 is useful for establishing guidelines. Although standard practice has favored using whole brain radiation therapy in patients with more than 4 lesions, a significant amount of normal brain tissue may be spared by treating these patients with SRS. SRS should be carefully considered in patients with multiple brain lesions, with the emphasis on total brain volume involved rather than the number of lesions to be treated.
Related Questions
What surrogate(s) do you use to determine toxicity/safety for a SRS plan with numerous metastases?
Before we turn to surrogates let us look at the information that a plan carries and has valuable implications on the quality of the work being done.First we record and report coverage, selectivity, conformity and gradient indices for every patient and every lesion.Second we plan in a consistent mann...
What is your cutoff for the maximum number and size of brain metastases that you will treat with SRS?
Sadly, the level 1 evidence needed to truly delineate the greatest benefits from SRS will probably never be realized beyound what we already know: SRS shows an OS benefit to pateint with 1 intracranial met and a CNS-DFS benefit to 2-3 mets. Beyond that, it's better in terms of preservation of neuroc...